A Note On Oncolytic Virus And Its Application In Cancer Treatment

Jump To References Section

Authors

  • Department of Biotechnology, Brainware University, Barasat, Kolkata-700125. ,IN

Keywords:

Oncolytic virus, Cancer cell retrogression, Immunotherapy.

Abstract

A naturally existing or genetically modified virus, that multiply selectively in cancer cells and destroy them without damaging healthy cells, can be termed as oncolytic virus. There are different kinds of oncolytic viruses which have different therapeutic applications in cancer treatment. Combination of viro-immunotherapy and conventional immunotherapy can achieve better results in cancer treatment. These possibilities are discussed.

Published

2022-06-01

Issue

Section

Articles

 

References

Apolonio, J. S,, de Souza, G. V. L, Santos, M. L. C., Luz, M. S., Souza, J. V. S., Pinheiro, S. L. R., de Souza, W. R., Loureiro, M. S. and de Melo, F. F. 2021. Oncolytic virus therapy in cancer: A current review. World J. Virol., 10(5): 229–255. https://doi.org/10.5501/wjv.v10.i5.229.

Bai, Y., Hui, P. and Su, X. 2019. Updates to the antitumor mechanism of oncolytic virus. Thorac. Cancer, 10(5): 1031-1035. https://doi.org/10.1111/1759-7714.13043 Garber, K. 2006, China approves world’s first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst., 98(5): 298-300.

Hobohm, U. 2001. Fever and cancer in perspective. Cancer Immunol. Immunother., 50(8): 391-396.

Menotti, L. and Avitabile, E. 2020. Herpes simplex virus oncolytic immunovirotherapy: the blossoming branch of multimodal therapy. Int. J. Mol. Sci., 21(21): 8310. https://doi.org/10.3390/ijms21218310.

Parato, K. A., Senger, D., Forsyth, P. A. and Bell, J. C. 2005. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer, 5(12): 965-976.

Puhlmann, J, Puehler, F, Mumberg, D, Boukamp, P. and Beier, R. 2010. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene, 29(15): 2205-2216.

Schirrmacher, V. and Fournier, P. 2009. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol., 542: 565-605. doi: 10.1007/978-1-59745-561-9_30.

A note on oncolytic virus and its application in cancer treatment

Shen, Y and Nemunaitis, J. 2005. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol. Ther, 11(2): 180-195.

Stojdl, D. F,, Lichty, B. D., tenOever, B. R., Paterson, J. M., Power, A. T. , Knowles, S., Marius, R., Reynard, J., Polquin, L., Atlcins, H., Brown, E. G., Durbin, R. K., Durbin, J. E., Hiscott, J. and Bell, J. C. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell., 4(4): 263-275.

Wen, X., Ding, L, Hunter, E, and Spearman, P. 2014. An siRNA screen of membrane trafficking genes highlights pathways common to HIV-1 and M-PMV virus assembly and release. / PLoS One., 9(9): e106151. doi: 10.1371/journal.pone.0106151

Wilden, H, Fournier, P, Zawatzky, R, and Schirrmacher, V. 2009. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by newcastle disease virus. Int. J. Oncol., 34(4): 971-982.

Zawitkowska, J., Lejman, M., Szmydki-Baran, A., Zaucha-Praźmo, A., Czyzewski, K., Dziedzic, M., Zalas-wiecek, P., Gryniewicz-Kwiatkowska, O., Czairiska-Deptula, A., Gletka, A., Semczuk, K., Hutnik, L., Chelmecka-Wilctorczyk, L., Zak, I., Frączkiewicz, J., Salamonowicz, M., Tomaszewska, R., Zając-Spychala, O., Irga-Jaworska, N., Bieri, E., Plonowsi, M., Bartnik, M., Ociepa, T., Pierlejewski, F., Machnik, K., Gamrot-Pyka, Z., Badowska, W., Brzeski, T., Urbanek-Dądela, A., Stolpa, W., Mizia-Malarz, A., Skowron-Kandzia, K., Musial, J. and Styczyriski, J. 2020. Varicella-zoster virus infection in the pediatric population with acute lymphoblastic leukemia in Poland. J. Med. Virol., 92(12): 3645-3649. https://doi.org/10.1002/jmv.26008